Caplice N M, West M J, Campbell G R, Campbell J
Department of Medicine, University of Queensland, Prince Charles Hospital, Brisbane, Australia.
Lancet. 1994 Jul 9;344(8915):97-8. doi: 10.1016/s0140-6736(94)91283-1.
We examined the inhibitory effect of heparin on vascular smooth muscle cell (VSMC) outgrowth from cultured coronary artery explants of primary atherosclerotic lesions and of undiseased regions from the same patients, compared with explant outgrowth from control patients (idiopathic cardiomyopathy) with no evidence of atherosclerosis. For undiseased tissue regardless of origin, heparin significantly delayed half-maximum percentage explant outgrowth time (mean difference from control treatment 2.1 [SE 0.8] days for atherosclerosis patients and 2.3 [1.0] days for control patients). For plaque tissue, heparin had no such effect. Thus the proliferative state of the cells involved in outgrowth may influence the activity of heparin.
我们研究了肝素对原发性动脉粥样硬化病变的培养冠状动脉外植体以及同一患者未患病区域的血管平滑肌细胞(VSMC)生长的抑制作用,并与无动脉粥样硬化证据的对照患者(特发性心肌病)的外植体生长进行了比较。对于无论来源的未患病组织,肝素显著延迟了外植体生长达到半数最大值的时间(动脉粥样硬化患者与对照治疗的平均差异为2.1 [标准误0.8]天,对照患者为2.3 [1.0]天)。对于斑块组织,肝素没有这种作用。因此,参与生长的细胞的增殖状态可能会影响肝素的活性。